Interview: Denis Delval – Senior Vice President, Europe West and South,…
ALK’s Denis Delval reveals how France is number one in terms of volumes for the group and number two in terms of revenues, just behind Germany; how the four Danes…
Address: 143/147 Bd Anatole France, Saint Denis 93285,France
Tel: +33 (0)1 55 87 30 00
The French Agency for the Safety of Health Products (AFSSAPS) was created by the Act of 1 July 1998 establishing a watchdog and security and safety. This is a public institution under the State supervision of the Ministry of Health. Afssaps’s mission is to ensure job security, quality and proper use of these health products.
Its jurisdiction applies to medicines and raw materials, medical devices and medical devices in vitro diagnostic (or laboratory reagents), for therapeutic products and biological products of human origin (labile blood products, organs, tissues, cells, products of gene and cell therapies), cosmetics and tattoo products.
AFSSAPS is an integeral piece of the public health system. Its activity assessment, monitoring and inspection is based on a high-level expertise to make available health products as safe as possible. It extends into the development and dissemination of information tailored to the needs of health professionals and the public. Moreover, AFSSAPS ensures that each patient receives treated products including pharmaceutical quality, the safety profile and efficacy are demonstrated and validated.
* Public Institution of the State created March 9, 1999, under supervision of the Minister for Health
* A team of nearly a thousand professionals
* More than 2,000 experts meeting in committees and working groups
* Laboratories in Saint-Denis, Lyon and Montpellier
* An operating budget of 109.6 million € for 2009
Pharmacopée
Actualité
Qu’est-ce que la Pharmacopée ?
La Pharmacopée française – 11e édition
Monographies en enquête publique
Réglementation
ALK’s Denis Delval reveals how France is number one in terms of volumes for the group and number two in terms of revenues, just behind Germany; how the four Danes…
The president and CEO of AREVA Med, the medical subsidiary of AREVA Group, the biggest nuclear company in the world, discusses the circumstances that inspired AREVA’s foray into nuclear medicine,…
The President of CEPS, the French pricing agency, reveals the issues around the launch of the hepatitis C drug Sovaldi in 2014 and of CEPS´ role to ensure that innovative products are available to all…
The President of Innothera talks about their unique business model, being in both the drug production and compression stockings businesses, how almost 95 percent of their drug production is exported,…
Olivier Pilley, French GM of the Swiss-American biotech company with a pioneering computational approach to anti-cancer therapies, presents ARIAD’s fascinating R&D model, his optimistic assessment of the competitiveness of the French…
The Director of the Social Security talks about the need to strengthen the sustainability of the French social security system, how France is attached to its unique system combining a…
The head of Aspen sterile operations and managing director of Aspen NDB, reveals how their facility in France acts as the main platform for the group´s sterile business, a market…
The CEO of Diaxonhit Group, a fully integrated French leader in in vitro diagnostics, discusses the company’s strategic focus on specialty vitro diagnostics, his perspective on the challenge of consolidation…
The Vice President of Health and Medicine at Pierre and Marie Curie University (UPMC) and Director of the University’s Institute of Oncology reveals how the French social security system needs…
The Director of the CNCR and the person in charge of the industrial sector, talk about the fragmented nature of French clinical research funding, why when it comes to boosting…
The President of France’s Association for CROs (AFCROs) discusses the issues surrounding France’s clinical research sector and the actions that both the public and private sector need to take to…
The president of Gedeon Richter France and CEO of PregLem, a Swiss-based biotech company acquired by Gedeon Richter in 2010, discusses the exciting synergies that have emerged from this partnership…
See our Cookie Privacy Policy Here